Original article| Volume 23, SUPPLEMENT 1, S99-S100, December 2001

Neurons and neuronal systems involved in the pathophysiologies of Rett syndrome

  • Henry G. Dunn
    Division of Neurology, Room A306, British Columbia's Children's Hospital, 4480 Oak Street, Vancouver, BC Canada V6H 3V4. Tel.: +1-604-875-2121; fax: +1-604-875-2285
    Department of Pediatrics, University of British Columbia, Vancouver, BC Canada
    Search for articles by this author


      It has long been suspected that the Rett syndrome (RS) is associated with abnormality of monoaminergic systems, particularly in the brainstem and midbrain, with spread to basal ganglia and cerebral cortex. Early investigators found no significant abnormality in the level of metabolites of noradrenaline, dopamine or serotonin in the spinal fluid, but autopsy brain studies revealed reduced levels of these substances and their metabolites as well as cortical choline acetyltransferase (ChAT) and microtubule-associated proteins (MAP). Levels of Substance P in spinal fluid of RS girls have been reported to be low, while levels of glutamate are raised. Attempts to assess dopaminergic activity by positron emission tomography (PET) in RS have given variable results with different reagents, including [18F] 6-fluorodopa. Our group investigated nine RS patients after the age of 12 years and control girls of similar age. Volumetric scans of basal ganglia with Magnetic Resonance Imaging showed a significant reduction in the size of caudate heads and thalami in RS (but not in the size of lentiform nuclei). PET scans with [11C] raclopride and with [18F] 6-fluorodopa under intravenous propofol anesthesia showed the mean uptake of fluorodopa to be reduced by 13.1% in caudate and by 12.4% in putamen as compared to the controls, whereas dopamine D2 receptor binding, as indicated by raclopride binding, was significantly increased by 9.7% in caudate and by 9.6% in putamen.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Brain and Development
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Nomura Y.
        • Segawa M.
        Anatomy of Rett syndrome.
        Am J Med Genet. 1986; 24: 289-303
        • Felten D.L.
        • Hallman H.
        • Jonsson G.
        Evidence for a neurotrophic role of noradrenaline neurons in the postnatal development of rat cerebral cortex.
        J Neurocytol. 1982; 11: 119-135
        • Perry T.L.
        • Dunn H.G.
        • Ho H.H.
        • Crichton J.U.
        Cerebrospinal fluid values for monoamine metabolites, gamma aminobutyric acid, and other amino compounds in Rett syndrome.
        J Pediatr. 1988; 112: 234-238
        • Lekman A.
        • Witt-Engerström I.
        • Holmberg B.
        • Percy A.
        • Svennerholm L.
        • Hagberg B.
        CSF and urine biogenic amine metabolites in Rett syndrome.
        Clin Genet. 1990; 37: 173-178
        • Lekman A.Y.
        • Hagberg B.A.
        • Svennerholm L.T.
        Membrane cerebral lipids in Rett syndrome.
        Pediatr Neurol. 1991; 7: 186-190
        • Wenk G.L.
        • Naidu S.
        • Casanova M.F.
        • Kitt C.A.
        • Moser H.
        Altered neurochemical markers in Rett's syndrome.
        Neurology. 1991; 41: 1753-1756
        • Johnston M.V.
        • Hohmann C.
        • Blue M.
        Neurobiology of Rett syndrome.
        Neuropediatrics. 1995; 26: 119-122
        • Kaufmann W.E.
        • Taylor C.V.
        • Hohmann C.F.
        • Sanwal I.B.
        • Naidu S.
        Abnormalities in neuronal maturation in Rett syndrome neocortex: preliminary molecular correlates.
        Eur Child Adolesc Psychiatry. 1997; 6: 75-77
        • Wenk G.L.
        • Hauss-Wegrzyniak B.
        Altered cholinergic function in the basal forebrain of girls with Rett syndrome.
        Neuropediatrics. 1999; 30: 125-129
        • Matsuishi T.
        • Nagamitsu S.
        • Yamashita Y.
        • Murakami Y.
        • Kimura A.
        • Sakai T.
        • et al.
        Decreased cerebrospinal fluid levels of substance P in patients with Rett syndrome.
        Ann Neurol. 1997; 42: 978-981
        • Deguchi K.
        • Antalffy B.A.
        • Twohill U.
        • Chakraborty S.
        • Glaze D.G.
        • Armstrong D.D.
        Substance P immunoreactivity in Rett syndrome.
        Pediatr Neurol. 2000; 22: 259-266
        • Stenbom Y.
        • Tonnby B.
        • Hagberg G.
        Lamotrigine in Rett syndrome: treatment experience from a pilot study.
        Eur Child Adolesc Psychiatry. 1998; 7: 49-52
        • Antonini A.
        • Vontobel P.
        • Psylla M.
        • Günther I.
        • Maguire P.R.
        • Missimer J.
        • et al.
        Complementary Positron Emission Tomographic studies of the striatal dopaminergic system in Parkinson's disease.
        Arch Neurol. 1995; 52: 1183-1190